V. CLAIMS

1. A method for creating treatment composition for treating, inhibiting, reducing, preventing, or reversing ~~a hair or skin disorder or treating erectile dysfunction~~ wrinkles or baldness, the method comprising:

identifying the hair color, hair type, skin color, skin type, race, ethnicity of an end user;

obtaining mesenchymal ~~skin~~ stem cells (MSCs) from a targeted donor having the same hair type, hair color, skin color, and/or ethnicity as the end user ~~or not susceptible to erectile dysfunction as the end user but with~~ ; wherein the MSC further comprise a single nucleotide polymorphism (SNP) profile that indicates the donor will never experience ~~hair disorder, skin disorder, or erectile dysfunction~~ wrinkles or baldness and can be gender, race, and ethnicity specific; and wherein the SNP comprises one or more SNPs present in one or more genes encoding Interleukin 18 (IL-18), Platelet Derived Growth Factor (PDGF) receptor (PDGFR) B (PDGFR-B), Tissue Inhibitors of Metalloprotease (TIMP) 1 (TIMP-1), TIMP-2, IL-23, Activin A, intrcellular adhesion molecule (ICAM-2), Plasminogen Activator Inhibitor-1 (PAI-1), Osteopontin (OPN), Insulin, Insulin growth factor binding protein four (IGF-BP4), Tumor Necrosis Factor (TNF) receptor (TNF-R), Neuregulin-1 B1 (NRG1-B1), Urokinase type Plasminogen Activator Receptor (uPAR), Ectodysplasin A2 receptor (XEDAR), follistatin, and/or activated leukocyte cell adhesion molecule (ALCAM); preferably, wherein the SNP comprises the IL-18 SNP rs1946518 (−607C>A) and/or rs187238 (−137G>C;

preparing ~~an~~ a powder preparation comprising MSC derived secretomes~~,~~ ~~keratinocytes, and melanocyte growth factor powder preparation from the obtained MSCs~~, wherein the MSC derived secretomes are obtained from MSCs ~~preparation comprises at least one member selected from the group consisting of cells or cell conditioned media cultured under normal hyperoxic culturing conditions and cells~~ cultured under harsh wound healing conditions; and

adding the powder preparation to a base,

wherein the treatment composition ~~comprises a member selected from the group consisting of~~ is a topical composition ~~and~~ or an injectable composition.

~~2. The method of claim 1, wherein the hair or skin disorder comprises hair greying, baldness, or skin discoloration.~~

~~3. The method of claim 2, wherein the skin discoloration results from vitiligo, melasma, strawberry nevus, or rosacea.~~

~~4. The method of claim 3, wherein the treatment composition corrects skin discoloration.~~

~~5~~2. The method of ~~claim 2~~ claim 1, wherein the baldness comprises male pattern baldness, androgenetic alopecia, alopecia areata, cicatricial alopecia, telogen effluvium, or female pattern baldness.

~~6~~3. The method of claim ~~5~~2, wherein the treatment composition stimulates the activation of hair follicles to promote hair growth.

~~7. The method of claim 2, wherein the treatment composition stimulates the production of hair pigmentation.~~

~~8. The method of claim 1, wherein the SNP comprises one or more SNPs present in one or more genes encoding Interleukin 18 (IL-18), Platelet Derived Growth Factor (PDGF) receptor (PDGFR) B (PDGFR-B), Tissue Inhibitors of Metalloprotease (TIMP) 1 (TIMP-1), TIMP-2, IL-23, Activin A, intrcellular adhesion molecule (ICAM-2), Plasminogen Activator Inhibitor-1 (PAI-1), Osteopontin (OPN), Insulin, Insulin growth factor binding protein four (IGF-BP4), Tumor Necrosis Factor (TNF) receptor (TNF-R), Neuregulin-1 B1 (NRG1-B1), Urokinase type Plasminogen Activator Receptor (uPAR), Ectodysplasin A2 receptor (XEDAR), follistatin, and/or activated leukocyte cell adhesion molecule (ALCAM).~~

~~9. The method of claim 1, wherein the SNP comprises the IL-18 SNP rs1946518 (-607C>A) and/or rs187238 (-137G>C).~~

~~10~~4. A treatment composition for treating, inhibiting, reducing, preventing, or reversing ~~a hair or skin disorder~~ wrinkles or baldness, the composition comprising:

a composition base; and

a powder preparation comprising mesenchymal stem cell (MSC) derived secretomes, ~~keratinocyte, and/or melanocyte growth factor powder preparation~~ wherein the MSC are derived from a donor having the same hair type, hair color, ~~hair~~ skin type, and/or ~~hair~~ skin color as an end user but with a single nucleotide polymorphism (SNP) profile that indicates the donor will never ~~the hair disorder and/or skin disorder~~ have wrinkles or baldness and can be gender, race, and ethnicity specific; wherein the SNP comprises one or more SNPs present in one or more genes encoding Interleukin 18 (IL-18), Platelet Derived Growth Factor (PDGF) receptor (PDGFR) B (PDGFR-B), Tissue Inhibitors of Metalloprotease (TIMP) 1 (TIMP-1), TIMP-2, IL-23, Activin A, intrcellular adhesion molecule (ICAM-2), Plasminogen Activator Inhibitor-1 (PAI-1), Osteopontin (OPN), Insulin, Insulin growth factor binding protein four (IGF-BP4), Tumor Necrosis Factor (TNF) receptor (TNF-R), Neuregulin-1 B1 (NRG1-B1), Urokinase type Plasminogen Activator Receptor (uPAR), Ectodysplasin A2 receptor (XEDAR), follistatin, and/or activated leukocyte cell adhesion molecule (ALCAM); preferably, wherein the SNP comprises the IL-18 SNP rs1946518 (−607C>A) and/or rs187238 (−137G>C; and wherein the MSC derived secretomes are obtained from MSCs ~~preparation comprises at least one member selected from the group consisting of cells or cell conditioned media cultured under normal hyperoxic culturing conditions and cells~~ cultured under harsh wound healing conditions.

~~11. The treatment composition of claim 10, wherein the SNP comprises one or more SNPs present in one or more genes encoding Interleukin 18 (IL-18), Platelet Derived Growth Factor (PDGF) receptor (PDGFR) B (PDGFR-B), Tissue Inhibitors of Metalloprotease (TIMP) 1 (TIMP-1), TIMP-2, IL-23, Activin A, intrcellular adhesion molecule (ICAM-2), Plasminogen Activator Inhibitor-1 (PAI-1), Osteopontin (OPN), Insulin, Insulin growth factor binding~~

protein four (IGF-BP4), Tumor Necrosis Factor (TNF) receptor (TNF-R), Neuregulin-1 B1 (NRG1-B1), Urokinase type Plasminogen Activator Receptor (uPAR), Ectodysplasin A2 receptor (XEDAR), follistatin, and/or activated leukocyte cell adhesion molecule (ALCAM).

12. The treatment composition of claim 10, wherein th.e SNP comprises the IL-18 SNP rs1946518 (-607C>A) and/or rs187238 (-137G>C)

13. The treatment composition of claim 10, wherein the hair disorder comprises baldness or grey hair.

145. The treatment composition of claim 4, wherein the baldness comprises male pattern baldness, androgenetic alopecia, alopecia areata, cicatricial alopecia, telogen effluvium, or female pattern baldness.

156. A method of treating a hair disorder comprising administering to a subject any of the treatment compositions of claim 4 or 5 any of claims 10-14.

16. The treatment composition of claim 10, wherein the skin disorder comprises skin discoloration that results from vitiligo, melasma, strawberry nevus, or rosacea.

177. A method of treating a skin disorder wrinkles comprising administering to a subject any of the treatment compositions of claim 4 any of claims 10-12 or 16.

188. A method for creating a skin treatment composition for the treatment of wrinkles and specific for a specific skin color, race, type, or ethnicity, the method comprising:

identifying the skin color, skin type, race, and ethnicity of an end user;

obtaining mesenchymal skin stem cells (MSCs) from a targeted donor having the same skin color, skin type, race, and ethnicity as the end user based on the donor's appropriate single nucleotide polymorphism panel profile;

preparing [[an]] a powder preparation comprising MSC derived secretomes, keratinocytes, and melanocyte growth factor powder preparation from the obtained MSCs, wherein the MSC derived secretomes are obtained from MSCs preparation comprises at least one member selected from the group consisting of cells or cell conditioned media cultured under normal hyperoxic culturing conditions and cells cultured under harsh wound healing conditions; and

adding the powder preparation to a cosmetic base.

19. A skin treatment composition for a specific skin color, race, type, or ethnicity, the composition comprising:

a composition base; and

a mesenchymal stem cell (MSC), keratinocyte, and/or melanocyte growth factor powder preparation derived from a donor having the same skin color, type race, and ethnicity as an end user, wherein the MSC preparation comprises at least one member selected from the group

~~consisting of cells or cell conditioned media cultured under normal hyperoxic culturing conditions and cells cultured under harsh wound healing conditions.~~